nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

03.07.2018 | Original Article

Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis

verfasst von: Di Zhao, Hui Liu, Pingshuan Dong

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The comparison of antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension has been investigated in several studies. The results were not consistent. We performed this meta-analysis determining the antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension.

Methods

Pubmed, Web of Science, and Cochrane Central were searched for all published randomized studies comparing the antihypertensive effects between azilsartan and olmesartan in patients with essential hypertension.

Results

The antihypertensive effects were assessed in 1402 patients included in five trials. The reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan (weighted mean differences (WMD) − 2.15 (95% confidence interval (CI), − 3.78, − 0.53) mm Hg, p < 0.01). There was no significant difference in reduction of office diastolic blood pressure between azilsartan and olmesartan (WMD − 0.99 (95% CI, − 2.06, 0.08) mm Hg, p > 0.05). The reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan at same dose for both drugs (WMD − 2.24 (95% CI, − 4.03, − 0.44) mm Hg, p < 0.05), whereas there was no significant difference in reduction of office diastolic blood pressure between azilsartan and olmesartan (WMD − 0.55 (95% CI, − 1.76, 0.66) mm Hg, p > 0.05).

Conclusions

This meta-analysis provides the evidence that the reduction of office systolic blood pressure treated with azilsartan was greater than olmesartan in patients with essential hypertension. These findings suggest the importance of strict designed randomized controlled trials in determining antihypertensive effects of angiotensin II receptor blockers in clinical practice.

Nishimura T, Hashimoto J, Ohkubo T, Kikuya M, Metoki H, Asayama K, Totsune K, Imai Y (2005) Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 27:477–489CrossRefPubMed

Hasegawa H, Takano H, Kameda Y, Kubota A, Kobayashi Y, Komuro I (2012) Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 34:86–91CrossRefPubMed

Georgiopoulos G, Katsi V, Oikonomou D, Vamvakou G, Koutli E, Laina A, Tsioufis C, Nihoyannopoulos P, Tousoulis D (2016) Azilsartan as a potent antihypertensive drug with possible pleiotropic cardiometabolic effects: a review study. Front Pharmacol 7:235CrossRefPubMedPubMedCentral

Baker WL, White WB (2011) Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 45:1506–1515CrossRefPubMed

Handley A, Lloyd E, Roberts A, Barger B (2016) Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. Clin Exp Hypertens 38:180–188CrossRefPubMedPubMedCentral

Kurtz TW, Kajiya T (2012) Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag 8:133–143CrossRefPubMedPubMedCentral

Kalikar M, Nivangune KS, Dakhale GN, Bajait CS, Sontakke SD, Motghare VM, Budania R (2017) Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage I hypertension: a randomized, open-label study. J Pharmacol Pharmacother 8:106–111PubMedPubMedCentral

Kario K, Saito I, Kushiro T, Teramukai S, Yaginuma M, Mori Y, Okuda Y, Kobayashi F, Shimada K (2016) Persistent olmesartan-based blood pressure-lowering effects on morning hypertension in Asians: the HONEST study. Hypertens Res 39:334–341CrossRefPubMedPubMedCentral

Costa FV (2017) Improving adherence to treatment and reducing economic costs of hypertension: the role of olmesartan-based treatment. High Blood Press Cardiovasc Prev 24:265–274CrossRefPubMed

10.

Kourlaba G, Gialama F, Tsioufis K, Maniadakis N (2016) A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. Int J Cardiol 221:60–74CrossRefPubMed

11.

White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S (2011) Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 57:413–420CrossRefPubMed

12.

Shiga Y, Miura SI, Motozato K, Norimatsu K, Yano M, Hitaka Y, Adachi S, Kuwano T, Inoue K, Inoue A, Fujisawa K, Shirotani T, Kusumoto T, Ideishi M, Saku K (2017) Comparison of efficacy and safety of azilsartan and olmesartan in patients with essential hypertension. Int Heart J 58:416–421CrossRefPubMed

13.

Kakio Y, Uchida HA, Umebayashi R, Takeuchi H, Okuyama Y, Hanayama Y, Wada J (2017) Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study). Blood Press Monit 22:59–67CrossRefPubMed

14.

Sezai A, Osaka S, Yaoita H, Arimoto M, Hata H, Shiono M, Sakino H (2016) Changeover trial of azilsartan and olmesartan comparing effects on the renin-angiotensin-aldosterone system in patients with essential hypertension after cardiac surgery (CHAOS study). Ann Thorac Cardiovasc Surg 22:161–167CrossRefPubMedPubMedCentral

15.

Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, Cao C, Kupfer S (2011) The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 13:81–88CrossRef

16.

Zhao D, Liu H, Dong P, Zhao J (2017) A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol 233:113–117CrossRefPubMed

17.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRef

18.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in metaanalyses. BMJ 327:557–560CrossRefPubMedPubMedCentral

19.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed

20.

Satoh M, Haga T, Hosaka M, Obara T, Metoki H, Murakami T, Kikuya M, Inoue R, Asayama K, Mano N, Ohkubo T, Imai Y (2016) The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements. J Hypertens 34:1218–1223CrossRefPubMed

21.

Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K (2013) Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 19:3002–3008CrossRefPubMed

22.

Angeloni E (2016) Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy. Core Evid 11:1–10CrossRefPubMedPubMedCentral

23.

Hjermitslev M, Grimm DG, Wehland M, Simonsen U, Krüger M (2017) Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension. Basic Clin Pharmacol Toxicol 121:225–233CrossRefPubMed

24.

Rakugi H, Enya K, Sugiura K, Ikeda Y (2012) Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 35:552–558CrossRefPubMedPubMedCentral

25.

Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S (2011) Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens 13:467–472CrossRef

26.

White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S (2016) Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens 34:788–797CrossRefPubMedPubMedCentral

27.

Iwanami J, Mogi M, Tsukuda K, Wang XL, Nakaoka H, Ohshima K, Chisaka T, Bai HY, Kanno H, Min LJ, Horiuchi M (2014) Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan. Hypertens Res 37:616–620CrossRefPubMed

28.

Harrell RE, Karim A, Zhang W, Dudkowski C (2016) Effects of age, sex, and race on the safety and pharmacokinetics of single and multiple doses of azilsartan medoxomil in healthy subjects. Clin Pharmacokinet 55:595–604CrossRefPubMed

29.

Raff U, Walker S, Ott C, Schneider MP, Schmieder RE (2015) Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. J Clin Hypertens 17:98–104CrossRef

30.

Akyürek Ö, Akbal E, Güneş F, Akyürek N (2014) Peroxisome proliferator-activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan. Arch Med Res 45:138–142CrossRefPubMed

31.

Ravarotto V, Pagnin E, Maiolino G, Fragasso A, Carraro G, Rossi B, Calò LA (2015) The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. J Renin-Angiotensin-Aldosterone Syst 16:1245–1250CrossRefPubMed

32.

Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, Shibata S, Tanaka M, Watanabe Y, Akasaka H, Ohnishi H, Yoshida H, Takizawa H, Saitoh S, Ura N, Shimamoto K, Miura T (2015) Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased byolmesartan, an angiotensin II receptor blocker. Am J Hypertens 28:15–21CrossRefPubMed

33.

Abe M, Oikawa O, Okada K, Soma M (2015) Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. J Renin-Angiotensin-Aldosterone Syst 16:159–164CrossRefPubMed

34.

Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E (2016) Olmesartan-induced enteropathy. Methodist Debakey Cardiovasc J 12:230–232CrossRefPubMedPubMedCentral

Titel: Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis
verfasst von: Di Zhao
Hui Liu
Pingshuan Dong
Publikationsdatum: 03.07.2018
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 2/2019
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-018-1859-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

An audit of healthcare professionals’ knowledge regarding perinatal autopsy

Spiritual care in neonatology: analysis of emergency baptisms in an Irish neonatal unit over 15 years

Ethical implications of population ageing in the intensive care unit

Irrational use of proton pump inhibitors in general practise

The identification of maternal smokers postnatally in an Irish maternity hospital